Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278171 | 0.95 | BCHE (0.42) | CASP3BCHEACHE | |
| SCHEMBL8354507 | 0.95 | BCHE (0.42) | CASP3BCHEACHE | |
| SCHEMBL8277392 | 0.94 | BCHE (0.36) | CASP3BCHEACHE | |
| SCHEMBL1509796 | 0.93 | CASP3 (0.43) | CASP3BCHE | |
| SCHEMBL1509798 | 0.93 | CASP3 (0.43) | CASP3BCHE | |
| SCHEMBL8346865 | 0.88 | CASP3 (0.38) | CASP3BCHE | |
| SCHEMBL12664613 | 0.88 | CASP3 (0.39) | CASP3BCHE | |
| SCHEMBL12569684 | 0.86 | MEN1 (0.47) | — | |
| SCHEMBL8278164 | 0.83 | BCHE (0.43) | BCHE | |
| SCHEMBL1857254 | 0.82 | BCHE (0.41) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-30 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531570-B2 | Treatment of diseases using ICE inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2003088917-A2 | REGULATION OF TNF-ALPHA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192094-A1 | TREATMENT OF DISEASES USING ICE INHIBITORS | UACA, SSB, NFKBIA | CASP3 425/4885BCHE 3379/4885ACHE 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.